RGNX REGENXBIO Inc
Price (delayed)
$7.05
Market cap
$353.11M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$4.59
Enterprise value
$375.58M
REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. REGENXBIO's NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform,
Highlights
RGNX's EPS is up by 24% year-on-year and by 9% since the previous quarter
The net income is up by 14% YoY and by 4.9% from the previous quarter
The quick ratio has declined by 9% since the previous quarter but it has increased by 8% year-on-year
RGNX's gross profit is up by 9% since the previous quarter but it is down by 6% year-on-year
The equity has contracted by 17% YoY and by 14% from the previous quarter
The company's revenue fell by 8% YoY
Key stats
What are the main financial stats of RGNX
Market
Valuations
Earnings
Shares outstanding
50.09M
Market cap
$353.11M
Enterprise value
$375.58M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.35
Price to sales (P/S)
4.19
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
4.51
Revenue
$83.33M
Gross profit
$49.76M
Operating income
-$233.35M
Net income
-$227.1M
EBIT
-$214.44M
EBITDA
-$198.23M
Free cash flow
-$175.56M
Per share
Balance sheet
Liquidity
EPS
-$4.59
EPS diluted
-$4.59
Free cash flow per share
-$3.55
Book value per share
$5.24
Revenue per share
$1.68
TBVPS
$9.41
Total assets
$465.99M
Total liabilities
$206.34M
Debt
$82.03M
Equity
$259.65M
Working capital
$174.81M
Debt to equity
0.32
Current ratio
2.69
Quick ratio
2.5
Net debt/EBITDA
-0.11
Margins
Efficiency
Dividend
EBITDA margin
-237.9%
Gross margin
59.7%
Net margin
-272.5%
Operating margin
-280%
Return on assets
-41.6%
Return on equity
-69.9%
Return on invested capital
-47.3%
Return on capital employed
-59.1%
Return on sales
-257.3%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
RGNX stock price
How has the REGENXBIO stock price performed over time
Intraday
4.29%
1 week
-14.02%
1 month
7.31%
1 year
-65.25%
YTD
-8.8%
QTD
-1.4%
Financial performance
How have REGENXBIO's revenue and profit performed over time
Revenue
$83.33M
Gross profit
$49.76M
Operating income
-$233.35M
Net income
-$227.1M
Gross margin
59.7%
Net margin
-272.5%
The net income is up by 14% YoY and by 4.9% from the previous quarter
The company's operating income rose by 13% YoY and by 5% QoQ
The gross margin has increased by 10% since the previous quarter
RGNX's gross profit is up by 9% since the previous quarter but it is down by 6% year-on-year
Growth
What is REGENXBIO's growth rate over time
Valuation
What is REGENXBIO stock price valuation
P/E
N/A
P/B
1.35
P/S
4.19
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
4.51
RGNX's EPS is up by 24% year-on-year and by 9% since the previous quarter
RGNX's P/B is 46% below its 5-year quarterly average of 2.4 and 28% below its last 4 quarters average of 1.8
The equity has contracted by 17% YoY and by 14% from the previous quarter
The price to sales (P/S) is 52% lower than the 5-year quarterly average of 8.4 and 44% lower than the last 4 quarters average of 7.2
The company's revenue fell by 8% YoY
Efficiency
How efficient is REGENXBIO business performance
RGNX's return on sales is up by 10% year-on-year and by 7% since the previous quarter
The ROIC has contracted by 5% YoY but it has grown by 2.9% from the previous quarter
REGENXBIO's ROA has decreased by 4% YoY
The ROE is down by 2.5% YoY
Dividends
What is RGNX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for RGNX.
Financial health
How did REGENXBIO financials performed over time
RGNX's total assets is 126% greater than its total liabilities
RGNX's total liabilities is down by 21% year-on-year and by 5% since the previous quarter
RGNX's total assets is down by 19% year-on-year and by 10% since the previous quarter
REGENXBIO's debt is 68% lower than its equity
The equity has contracted by 17% YoY and by 14% from the previous quarter
RGNX's debt to equity is up by 14% since the previous quarter and by 10% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.